Secondary non-Hodgkin's lymphoma after treatment for childhood cancer.

José M. Eguiguren(St. Jude Children's Research Hospital), WM Crist(Unknown), David R. Head(University of Southern California), R. C. Ribeiro(St. Jude Children's Research Hospital), CH Pui(St. Jude Children's Research Hospital), M L Hancock(St. Jude Children's Research Hospital), C B Pratt

PubMed

October 1, 1991

Cited by 18

Related Papers

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

|Blood|2000|1.6k

Age and acute myeloid leukemia

|Blood|2006|1.4k

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

|Journal of Clinical Oncology|1996|920

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

|Blood|1997|869

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

|Journal of Clinical Oncology|1990|786